Online inquiry

IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3901MR)

This product GTTS-WQ3901MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3901MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6891MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ15759MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ3430MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ7652MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ1038MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ9392MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ15383MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ8139MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW